Liquidia Technologies Inc

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Liquidia Technologies reports robust Q4 earnings, eyes YUTREPIA's market potential

Liquidia Technologies Inc (LQDA) showcased strong financial performance and promising prospects for its flagship product, YUTREPIA, in the pharmaceutical market. While facing challenges in legal proceedings and market competition, the company's focus on innovation, clinical trials, and strategic positioning bodes well for future growth and success.

Liquidia Technologies navigates legal hurdles to capitalize on YUTREPIA

Liquidia Technologies faces financial challenges with a net loss in Q1 2023 but holds a strong cash position. The success of YUTREPIA hinges on navigating legal hurdles and effectively differentiating itself in the market.

Liquidia Technologies reports solid Q2 results amidst legal victories

Liquidia Technologies Inc's Q2 2023 Earnings Call highlighted strong financials, legal victories, and strategic focus on R&D. While facing legal challenges and balancing expenses, the company remains confident in its progress. Opportunities in FDA approvals, clinical development, and strategic partnerships present avenues for growth.

Liquidia Technologies Inc (LQDA) reports strong progress and prepares for market expansion

Liquidia Technologies Inc (LQDA) made significant strides in developing inhaled treprostinil products, showcasing promising results and clear benefits.
While facing regulatory and market challenges, the company's strong commercial preparations and financial prudence position it well for future growth.
Opportunities in market expansion, successful product launches, and program development offer avenues for revenue growth and industry leadership.

Liquidia Technologies eyes FDA approval for YUTREPIA, targeting $3B market

Liquidia Technologies is poised for growth with a strong financial position and strategic focus on YUTREPIA to lead the treprostinil market.
While facing regulatory and operational challenges, the company's emphasis on addressing patient dosing effectively presents opportunities for market leadership.
The potential FDA approval of YUTREPIA post-March 31 opens doors to a $3 billion market opportunity, positioning the company for significant growth.

Liquidia Technologies reports strong Q1 performance and eyes market expansion

Liquidia Technologies Inc's Q1 2024 earnings call highlighted strong financial performance, market potential in inhaled treprostinil products, legal progress, and a focus on innovation. The company is well-positioned for commercial launch post-approval and aims to address the growing market demand for improved treatment options.

Liquidia Technologies reports Q2 results, eyes pulmonary hypertension market

Liquidia Technologies Inc reported mixed financial results for Q2 2024, with revenue of $3.7 million and a net loss.
The company's focus on YUTREPIA and L606 formulations presents promising opportunities in the pulmonary hypertension space.
Analyst inquiries highlighted key areas of interest, including product benefits, trial data, regulatory matters, and financial outlook.
With a strong cash position and ongoing FDA engagement, Liquidia is poised for potential growth and advancement in its pipeline.

Liquidia Technologies reports strong Q3 performance amidst regulatory challenges

Liquidia Technologies Inc's Q3 2024 Earnings Call highlighted strong financial performance, progress towards YUTREPIA approval, and strategic plans for product launch. Legal challenges and regulatory hurdles pose significant challenges, while opportunities for growth exist in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July 18, 2022.

Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer

MORRISVILLE, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the Pulmonary Hypertension Association (PHA) International Conference and Scientific Session in Atlanta, Georgia, June 9 to 11, 2022.

Liquidia Announces Presentation at the 2022 Pulmonary Hypertension Association (PHA) International Conference

MORRISVILLE, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today an update to the company's participation in the Jefferies Healthcare Conference. Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat on Thursday, June 9, 2022, now scheduled for 8:00 am Eastern Time. The conference is taking place June 8-10, 2022, in New York City.

Update to Liquidia's Participation in the Jefferies Healthcare Conference

AcelRx Pharmaceuticals

TOMI Environmental Solutions

Here's what you need to know about trading penny stocks on June 3rd The post What to Know About Buying Penny Stocks on June 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 3rd

MORRISVILLE, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:00 am Eastern Time. The conference is taking place June 8-10, 2022, in New York City.

Liquidia to Participate in the Jefferies Healthcare Conference

A major bank initiated coverage of the stock with a very bullish recommendation and price target.

Why Liquidia Stock Rose as Much as 22% Higher Today

MORRISVILLE, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the America Thoracic Society (ATS) International Conference 2022 in San Francisco, California.

Liquidia Announces Presentations at the 2022 American Thoracic Society (ATS) International Conference

Liquidia Corporation(NASDAQ:LQDA ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Mike Kaseta - CFO Rusty Schundler - General Counsel Conference Call Participants Serge Belanger - Needham & Company Julian Harrison - BTIG Andreas Argyrides - Wedbush Operator Good morning, and welcome, everyone, the Liquidia Corporation First Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Howard, and I will be your conference operator today.

Liquidia Corporation (LQDA) CEO Roger Jeffson Q12022 Results - Earnings Call Transcript

-  Secured access to new capital through debt and equity transactions

Liquidia Reports First Quarter 2022 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., May 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2022 financial results on Thursday, May 12, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

Liquidia to Report First Quarter 2022 Financial Results on May 12, 2022

Affirm

CCC Intelligent Solutions Holdings

Alphabet

Lyra Therapeutics

Rocket Companies, Inc.

CBRE Global Real Estate Income Fund

These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared first on InvestorPlace.

7 Stocks to Watch for Major Insider Trading Clues

MORRISVILLE, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandeep Sahay, MD, from Houston Methodist Hospital will present clinical data from studies of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT) in Boston, Massachusetts.

Liquidia Announces Oral Presentation at the 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT)

MORRISVILLE, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) today announced the closing of its previously announced underwritten public offering of 11,274,510 shares of its common stock, which includes full exercise of the underwriters' over-allotment option to purchase 1,470,588 additional shares of common stock, at a public offering price of $5.10 per share, for total gross proceeds of approximately $57.5 million before deducting underwriting discounts and commissions and expenses payable by Liquidia. All shares in the offering were sold by Liquidia.

Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option

MORRISVILLE, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) announced today that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Liquidia Announces Proposed Offering of Common Stock

Liquidia Corporation's (LQDA) CEO Roger Jeffs on Q4 2021 Results - Earnings Call Transcript

- Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder

Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update

Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.

Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?

MORRISVILLE, N.C., March 10, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2021 financial results on Thursday, March 17, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022

IVERIC bio Inc

Sensus Healthcare

Biotech has been the worst performing sector of the stock market across the past 12 months.

Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market

MORRISVILLE, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at closing. Liquidia initially entered a debt facility with SVB in March 2021 that provided up to $20.5 million in term loans of which $10.5 million had been funded to date.

Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million

MORRISVILLE, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director of the Company and will provide transition support through January 31, 2022.

Liquidia Corporation Announces Chief Executive Officer Transition

MORRISVILLE, N.C., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 (‘901 patent) in the on-going litigation under the Hatch-Waxman Act (Hatch-Waxman). Under the stipulation of partial judgment, UTC has agreed to the entry of judgment of Liquidia's non-infringement of the '901 patent based on the Court's construction of certain terms in the patent. UTC has preserved its appellate rights with respect to the ‘901 patent in the event the Court's construction of those terms is reversed. With this stipulation of partial judgment, only U.S. Patent No. 9,593,066 (‘066 patent) will now serve as a basis for the on-going regulatory stay for final approval of YUTREPIA™ (treprostinil) inhalation powder by the U.S. Food and Drug Administration (FDA).

Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation

Compass Therapeutics

 Orbital Energy Group, Inc.

OpGen

PetVivo Holdings

Hot penny stocks insiders are buying in November The post 5 Penny Stocks To Buy Now According To Insiders In November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy Now According To Insiders In November 2021

Endo International

New Gold

The Real Brokerage Inc.

ReTo Eco-Solutions

Can you make money in the stock market with a full time job? The post Best Penny Stocks To Buy With A Full-Time Job?

Best Penny Stocks To Buy With A Full-Time Job? 5 Hit It Big In Q4 2021

MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference being held November 16-19, 2021 . The fireside chat will be available to registered participants on-demand beginning at 8:00 a.m. GMT on November 18, 2021.

News for Liquidia Technologies Inc Stock (LQDA)